ResApp Health Limited announced that SMARTCOUGH-C-2, a prospective, multi-site, double blind study that will evaluate the efficacy of the ResAppDx smartphone application in the diagnosis of childhood respiratory diseases from cough sounds, has secured its third institutional review board (IRB) approval in the United States. Three hospital sites in the United States have now received IRB approval for the study Massachusetts General Hospital, Texas Children's Hospital and Cleveland Clinic Children's, which obtained approval in January 2018. The SMARTCOUGH-C-2 study plans to enrol up to 1,667 patients aged 29 days to 12 years of age who present to one of the three participating sites in the United States with signs or symptoms of respiratory disease. The study's co-primary endpoints are positive and negative percent agreement with clinical diagnosis for pneumonia, lower respiratory tract disease, viral lower respiratory tract infection, bronchiolitis, asthma/reactive airways disease, upper respiratory tract disease and croup. The clinical diagnosis will be made by an independent, centralised clinical adjudication committee using all available clinical data, including radiology and microbiology.